{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:38:25Z","timestamp":1792165105682,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1038\/s41401-021-00770-w","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T07:19:32Z","timestamp":1634023172000},"page":"1913-1920","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases"],"prefix":"10.1038","volume":"42","author":[{"given":"An-te","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-fei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-ping","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-fei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ge","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-zhuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"770_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801\u201310.","journal-title":"JAMA"},{"key":"770_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study. Lancet. 2020;395:200\u201311.","journal-title":"Lancet"},{"key":"770_CR3","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1097\/CCM.0000000000004155","volume":"48","author":"J Xie","year":"2020","unstructured":"Xie J, Wang H, Kang Y, Zhou L, Liu Z, Qin B, et al. The epidemiology of sepsis in Chinese ICUs: a national cross-sectional survey. Crit Care Med. 2020;48:e209\u2013e18.","journal-title":"Crit Care Med"},{"key":"770_CR4","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.3389\/fimmu.2018.02147","volume":"9","author":"GL Lin","year":"2018","unstructured":"Lin GL, McGinley JP, Drysdale SB, Pollard AJ. Epidemiology and immune pathogenesis of viral sepsis. Front Immunol. 2018;9:2147.","journal-title":"Front Immunol"},{"key":"770_CR5","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(20)30920-X","volume":"395","author":"H Li","year":"2020","unstructured":"Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395:1517\u201320.","journal-title":"Lancet"},{"key":"770_CR6","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1161\/CIRCULATIONAHA.120.050753","volume":"142","author":"MJ Ponsford","year":"2020","unstructured":"Ponsford MJ, Gkatzionis A, Walker VM, Grant AJ, Wootton RE, Moore LSP, et al. Cardiometabolic traits, sepsis, and severe COVID-19: a mendelian randomization investigation. Circulation. 2020;142:1791\u20133.","journal-title":"Circulation"},{"key":"770_CR7","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S2213-2600(20)30217-4","volume":"8","author":"KE Remy","year":"2020","unstructured":"Remy KE, Brakenridge SC, Francois B, Daix T, Deutschman CS, Monneret G, et al. Immunotherapies for COVID-19: lessons learned from sepsis. Lancet Respir Med. 2020;8:946\u20139.","journal-title":"Lancet Respir Med"},{"key":"770_CR8","doi-asserted-by":"publisher","first-page":"16045","DOI":"10.1038\/nrdp.2016.45","volume":"2","author":"RS Hotchkiss","year":"2016","unstructured":"Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Prim. 2016;2:16045.","journal-title":"Nat Rev Dis Prim"},{"key":"770_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41581-018-0005-7","volume":"14","author":"C Lelubre","year":"2018","unstructured":"Lelubre C, Vincent JL. Mechanisms and treatment of organ failure in sepsis. Nat Rev Nephrol. 2018;14:417\u201327.","journal-title":"Nat Rev Nephrol"},{"key":"770_CR10","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1164\/rccm.201612-2460PP","volume":"197","author":"KC Ma","year":"2018","unstructured":"Ma KC, Schenck EJ, Pabon MA, Choi AMK. The role of danger signals in the pathogenesis and perpetuation of critical illness. Am J Respir Crit Care Med. 2018;197:300\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"770_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-immunol-030409-101323","volume":"29","author":"U Andersson","year":"2011","unstructured":"Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139\u201362.","journal-title":"Annu Rev Immunol"},{"key":"770_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.immuni.2014.04.001","volume":"40","author":"CS Deutschman","year":"2014","unstructured":"Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity. 2014;40:463\u201375.","journal-title":"Immunity."},{"key":"770_CR13","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.15252\/embj.201694696","volume":"35","author":"L Sborgi","year":"2016","unstructured":"Sborgi L, R\u00fchl S, Mulvihill E, Pipercevic J, Heilig R, Stahlberg H, et al. GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death. EMBO J. 2016;35:1766\u201378.","journal-title":"EMBO J"},{"key":"770_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nature18629","volume":"535","author":"X Liu","year":"2016","unstructured":"Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016;535:153\u20138.","journal-title":"Nature"},{"key":"770_CR15","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cell.2014.04.007","volume":"157","author":"M Lamkanfi","year":"2014","unstructured":"Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014;157:1013\u201322.","journal-title":"Cell."},{"key":"770_CR16","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/cr.2015.139","volume":"25","author":"WT He","year":"2015","unstructured":"He WT, Wan H, Hu L, Chen P, Wang X, Huang Z, et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1beta secretion. Cell Res. 2015;25:1285\u201398.","journal-title":"Cell Res"},{"key":"770_CR17","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41590-020-0669-6","volume":"21","author":"JJ Hu","year":"2020","unstructured":"Hu JJ, Liu X, Xia S, Zhang Z, Zhang Y, Zhao J, et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol. 2020;21:736\u201345.","journal-title":"Nat Immunol"},{"key":"770_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.freeradbiomed.2020.03.007","volume":"152","author":"W Deng","year":"2020","unstructured":"Deng W, Yang Z, Yue H, Ou Y, Hu W, Sun P. Disulfiram suppresses NLRP3 inflammasome activation to treat peritoneal and gouty inflammation. Free Radic Biol Med. 2020;152:8\u201317.","journal-title":"Free Radic Biol Med"},{"key":"770_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1600-0447.1992.tb03310.x","volume":"86","author":"B Johansson","year":"1992","unstructured":"Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl. 1992;86:15\u201326.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"770_CR20","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1021\/nn4010796","volume":"7","author":"X Duan","year":"2013","unstructured":"Duan X, Xiao J, Yin Q, Zhang Z, Yu H, Mao S, et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano. 2013;7:5858\u201369.","journal-title":"ACS Nano"},{"key":"770_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.intimp.2019.01.036","volume":"70","author":"N Deng","year":"2019","unstructured":"Deng N, Li M, Shen D, He Q, Sun W, Liu M, et al. LRP1 receptor-mediated immunosuppression of alpha-MMC on monocytes. Int Immunopharmacol. 2019;70:80\u20137.","journal-title":"Int Immunopharmacol"},{"key":"770_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1055\/s-0038-1639359","volume":"35","author":"P Manzoni","year":"2018","unstructured":"Manzoni P, Dall\u2019Agnola A, Tom\u00e9 D, Kaufman DA, Tavella E, Pieretto M, et al. Role of lactoferrin in neonates and infants: an update. Am J Perinatol. 2018;35:561\u20135.","journal-title":"Am J Perinatol"},{"key":"770_CR23","doi-asserted-by":"publisher","first-page":"120355","DOI":"10.1016\/j.biomaterials.2020.120355","volume":"263","author":"AO Elzoghby","year":"2020","unstructured":"Elzoghby AO, Abdelmoneem MA, Hassanin IA, Abd Elwakil MM, Elnaggar MA, Mokhtar S, et al. Lactoferrin, a multi-functional glycoprotein: active therapeutic, drug nanocarrier & targeting ligand. Biomaterials. 2020;263:120355.","journal-title":"Biomaterials."},{"key":"770_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","volume":"6","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, et al. Ulcerative colitis. Nat Rev Dis Prim. 2020;6:74.","journal-title":"Nat Rev Dis Prim"},{"key":"770_CR25","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769\u201378.","journal-title":"Lancet"},{"key":"770_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(19)32545-0","volume":"395","author":"O Ol\u00e9n","year":"2020","unstructured":"Ol\u00e9n O, Erichsen R, Sachs MC, Pedersen L, Halfvarson J, Askling J, et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet. 2020;395:123\u201331.","journal-title":"Lancet"},{"key":"770_CR27","first-page":"269","volume":"2","author":"S Bopanna","year":"2017","unstructured":"Bopanna S, Ananthakrishnan AN, Kedia S, Yajnik V, Ahuja V. Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis. Lancet. Gastroenterol Hepatol. 2017;2:269\u201376.","journal-title":"Gastroenterol Hepatol"},{"key":"770_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1473-3099(15)70112-X","volume":"15","author":"J Cohen","year":"2015","unstructured":"Cohen J, Vincent JL, Adhikari NK, Machado FR, Angus DC, Calandra T, et al. Sepsis: a roadmap for future research. Lancet Infect Dis. 2015;15:581\u2013614.","journal-title":"Lancet Infect Dis"},{"key":"770_CR29","doi-asserted-by":"publisher","first-page":"i1585","DOI":"10.1136\/bmj.i1585","volume":"353","author":"JE Gotts","year":"2016","unstructured":"Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ. 2016;353:i1585.","journal-title":"BMJ."},{"key":"770_CR30","doi-asserted-by":"publisher","first-page":"107476","DOI":"10.1016\/j.pharmthera.2020.107476","volume":"208","author":"F Steinhagen","year":"2020","unstructured":"Steinhagen F, Schmidt SV, Schewe JC, Peukert K, Klinman DM, Bode C. Immunotherapy in sepsis - brake or accelerate? Pharmacol Ther. 2020;208:107476.","journal-title":"Pharmacol Ther"},{"key":"770_CR31","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ki.2008.442","volume":"74","author":"MP Fink","year":"2008","unstructured":"Fink MP. Animal models of sepsis and its complications. Kidney Int. 2008;74:991\u20133.","journal-title":"Kidney Int"},{"key":"770_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.intimp.2011.11.002","volume":"12","author":"ME Drago-Serrano","year":"2012","unstructured":"Drago-Serrano ME, de la Garza-Amaya M, Luna JS, Campos-Rodriguez R. Lactoferrin-lipopolysaccharide (LPS) binding as key to antibacterial and antiendotoxic effects. Int Immunopharmacol. 2012;12:1\u20139.","journal-title":"Int Immunopharmacol"},{"key":"770_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1046\/j.1365-2249.2002.01956.x","volume":"130","author":"ML Kruzel","year":"2002","unstructured":"Kruzel ML, Harari Y, Mailman D, Actor JK, Zimecki M. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin Exp Immunol. 2002;130:25\u201331.","journal-title":"Clin Exp Immunol"},{"key":"770_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.intimp.2012.12.009","volume":"15","author":"MF Doursout","year":"2013","unstructured":"Doursout MF, Horton H, Hoang L, Liang Y, Hwang SA, Boyd S, et al. Lactoferrin moderates LPS-induced hypotensive response and gut injury in rats. Int Immunopharmacol. 2013;15:227\u201331.","journal-title":"Int Immunopharmacol"},{"key":"770_CR35","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.3389\/fimmu.2017.01438","volume":"8","author":"ML Kruzel","year":"2017","unstructured":"Kruzel ML, Zimecki M, Actor JK. Lactoferrin in a context of inflammation-induced pathology. Front Immunol. 2017;8:1438.","journal-title":"Front Immunol"},{"key":"770_CR36","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMra1102942","volume":"365","author":"S Danese","year":"2011","unstructured":"Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713\u201325.","journal-title":"N Engl J Med"},{"key":"770_CR37","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756\u201370.","journal-title":"Lancet"},{"key":"770_CR38","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/j.1365-2036.2011.04599.x","volume":"33","author":"L Peyrin-Biroulet","year":"2011","unstructured":"Peyrin-Biroulet L, L\u00e9mann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:870\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"770_CR39","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41575-019-0172-4","volume":"16","author":"YR Na","year":"2019","unstructured":"Na YR, Stakenborg M, Seok SH, Matteoli G. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nat Rev Gastroenterol Hepatol. 2019;16:531\u201343.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"770_CR40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41577-018-0002-x","volume":"18","author":"AM Mowat","year":"2018","unstructured":"Mowat AM. To respond or not to respond - a personal perspective of intestinal tolerance. Nat Rev Immunol. 2018;18:405\u201315.","journal-title":"Nat Rev Immunol"},{"key":"770_CR41","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.apsb.2020.07.019","volume":"10","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Yang Y, Zhang J, Wang R, Cheng B, Kalambhe D, et al. Lactoferrin-mediated macrophage targeting delivery and patchouli alcohol-based therapeutic strategy for inflammatory bowel diseases. Acta Pharm Sin B. 2020;10:1966\u201376.","journal-title":"Acta Pharm Sin B"},{"key":"770_CR42","first-page":"S","volume":"156","author":"EM Davis","year":"2019","unstructured":"Davis EM, Zhang D, Glover SC, Stappenbeck TS, Liu JJ. Su1832 \u2013 inhibition of intestinal epithelial cell pyroptosis and associated mucosal barrier defects is a potential therapeutic mechanism of action for mesalamine in Ibd. Gastroenterology. 2019;156:S\u2013627.","journal-title":"Gastroenterology"},{"key":"770_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/1751-2980.12831","volume":"21","author":"TH Ren","year":"2020","unstructured":"Ren TH, Lv MM, An XM, Leung WK, Seto WK. Activation of adenosine A3 receptor inhibits inflammatory cytokine production in colonic mucosa of patients with ulcerative colitis by down-regulating the nuclear factor-kappa B signaling. J Dig Dis. 2020;21:38\u201345.","journal-title":"J Dig Dis"},{"key":"770_CR44","first-page":"2695","volume":"22","author":"X Wu","year":"2020","unstructured":"Wu X, Pan S, Luo W, Shen Z, Meng X, Xiao M, et al. Roseburia intestinalis\u2011derived flagellin ameliorates colitis by targeting miR\u2011223\u20113p\u2011mediated activation of NLRP3 inflammasome and pyroptosis. Mol Med Rep. 2020;22:2695\u2013704.","journal-title":"Mol Med Rep."}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00770-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00770-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00770-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:27:37Z","timestamp":1744180057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00770-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1038\/s41401-021-00770-w","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,24]]},"assertion":[{"value":"21 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}